Crossmark

Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway

Crossref DOI link: https://doi.org/10.1186/s12906-018-2297-3

Published Online: 2018-08-09

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Hongbo

Wang, Zhenkai

Zhang, Jie

Wang, Youlei

Yu, Chen

Zhang, Jinjin

Song, Xiaodong

Lv, Changjun
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (31470415)

National Natural Science Foundation of China (31670365)

National Natural Science Foundation of China (81670064)

National Natural Science Foundation of China (81741170)

National Natural Science Foundation of China (81273957)

National Natural Science Foundation of China (ZR2016HP34)
License Information

Text and Data Mining valid from 2018-08-09
More Information

Article History

Received: 17 April 2018

Accepted: 26 July 2018

First Online: 9 August 2018

Ethics approval and consent to participate

: We had complied with the ethics standard for research activity established at Binzhou Medical University. This research work was approved by Ethical Review Committee of Binzhou Medical University, China (Approval number: No. 201704001).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.